<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486329</url>
  </required_header>
  <id_info>
    <org_study_id>VXM01-01-DE</org_study_id>
    <nct_id>NCT01486329</nct_id>
  </id_info>
  <brief_title>VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer</brief_title>
  <official_title>VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaximm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaximm GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human phase I dose escalation study in patients with locally advanced, inoperable&#xD;
      and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the&#xD;
      investigational VEGFR-2 DNA vaccine VXM01 to examine safety and tolerability, clinical and&#xD;
      immunogenic response to the investigational vascular endothelial growth factor receptor 2&#xD;
      (VEGFR-2) DNA vaccine VXM01, and to define the maximum tolerated dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>38 days</time_frame>
    <description>Number of dose-limiting toxicities and maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of immune positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor staging</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Tumor staging according to RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor perfusion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Tumor perfusion determined by DCE-MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>VXM01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational anti-angiogenic live cancer vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXM01</intervention_name>
    <description>Live anti-angiogenic cancer vaccine drink solution, escalating dose</description>
    <arm_group_label>VXM01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drink solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent, signed and dated&#xD;
&#xD;
          -  Locally advanced, inoperable and stage IV pancreatic cancer patients according to UICC&#xD;
             based on diagnostic imaging using computer-tomography (CT) or histological&#xD;
             examinations&#xD;
&#xD;
          -  Male or post-menopausal female&#xD;
&#xD;
          -  Age above or equal to 18 years&#xD;
&#xD;
          -  Chemotherapy naïve within 60 days before screening visit except gemcitabine treatment&#xD;
&#xD;
          -  Karnovsky index &gt;70&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
          -  Adequate renal, hepatic, and bone marrow function&#xD;
&#xD;
          -  Absolute neutrophil count &gt;1500/µL&#xD;
&#xD;
          -  Hemoglobin &gt;10 g/dL&#xD;
&#xD;
          -  Platelets &gt;75000/µL&#xD;
&#xD;
          -  Prothrombin time and international normalized ratio (INR) &lt;1.5 times upper limit of&#xD;
             normal (ULN) (except under anticoagulant treatment)&#xD;
&#xD;
          -  Aspartate aminotransferase &lt;4 times ULN&#xD;
&#xD;
          -  Alanine aminotransferase &lt;4 times ULN&#xD;
&#xD;
          -  Total bilirubin &lt;3 times ULN&#xD;
&#xD;
          -  Creatinine clearance estimated according to Cockcroft-Gault &gt;30 mL/min&#xD;
&#xD;
          -  Proteinuria &lt;1 g protein on 24 h urine collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  State after pancreas resection (complete or partial)&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
          -  Drug trial participation within 60 days before screening visit&#xD;
&#xD;
          -  Other previous or current malignancy except basal or squamous cell skin cancer, in&#xD;
             situ cervical cancer, or any other cancer from which the patient has been disease-free&#xD;
             for &lt;2 years&#xD;
&#xD;
          -  Prior vaccination with Ty21a&#xD;
&#xD;
          -  Cardiovascular disease defined as:&#xD;
&#xD;
               -  Uncontrolled hypertension (systolic blood pressure &gt;160 mmHg or diastolic blood&#xD;
                  pressure &gt;100 mmHg)&#xD;
&#xD;
               -  Arterial thromboembolic event within 6 months before randomization including:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
          -  Congestive heart failure New York Heart Association grade III to IV&#xD;
&#xD;
          -  Serious ventricular arrhythmia requiring medication&#xD;
&#xD;
          -  Clinically significant peripheral artery disease &gt; grade 2b according to Fontaine&#xD;
&#xD;
          -  Hemoptysis within 6 months before randomization&#xD;
&#xD;
          -  Esophageal varices&#xD;
&#xD;
          -  Upper or lower gastrointestinal bleeding within 6 months before randomization&#xD;
&#xD;
          -  Significant traumatic injury within 4 weeks before randomization&#xD;
&#xD;
          -  Non-healing wound, bone fracture or any history of gastrointestinal ulcers within&#xD;
             three years before inclusion, or positive gastroscopy within 3 months before inclusion&#xD;
&#xD;
          -  Gastrointestinal fistula&#xD;
&#xD;
          -  Thrombolysis therapy within 4 weeks before randomization&#xD;
&#xD;
          -  Bowel obstruction within the last 30 days before screening visit&#xD;
&#xD;
          -  Liver cirrhosis ≥ grade B according to Child-Pugh Score-Classification&#xD;
&#xD;
          -  Presence of any acute or chronic systemic infection&#xD;
&#xD;
          -  Radiotherapy within 4 weeks before randomization&#xD;
&#xD;
          -  Major surgical procedures, or open biopsy within 4 weeks before randomization&#xD;
&#xD;
          -  Fine needle aspiration within 7 days before randomization&#xD;
&#xD;
          -  Chronic concurrent therapy within 2 weeks before and during the double-blind study&#xD;
             period with:&#xD;
&#xD;
               -  Corticosteroids (except steroids for adrenal failure) or immunosuppressive agents&#xD;
&#xD;
               -  Antibiotics&#xD;
&#xD;
               -  Bevacizumab&#xD;
&#xD;
               -  Any epidermal growth factor receptor inhibitor&#xD;
&#xD;
               -  Chemotherapy except gemcitabine before Day 10&#xD;
&#xD;
          -  Multi-drug resistant gram-negative germ&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that might affect the&#xD;
             interpretation of the study results or render the patient at high risk for treatment&#xD;
             complications&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Any history of drug hypersensitivity&#xD;
&#xD;
          -  Any condition which results in an undue risk for the patient during the study&#xD;
             participation according to the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinics, Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of General Surgery</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>June 5, 2015</last_update_submitted>
  <last_update_submitted_qc>June 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Cancer vaccine</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Inoperable</keyword>
  <keyword>Gemcitabine chemotherapy</keyword>
  <keyword>Locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

